CARBOGEN AMCIS

CARBOGEN AMCIS was acquired by Dishman in August 2006. CARBOGEN AMCIS is a leading service provider, offering a portfolio of drug development and commercialisation services to the pharmaceutical and biopharmaceutical industries at all stages of drug development. The integrated services of CARBOGEN AMCIS provide innovative chemistry solutions to support timely and safe drug development with improved cost efficiency.

CARBOGEN AMCIS’ focus is on supporting the development process from bench to market. The breadth of capabilities span contract chemical process research and development to the supply of Active Pharmaceutical Ingredients (APIs) for preclinical studies, clinical trials and commercial use. CARBOGEN AMCIS site in Riom, France is fully dedicated to the formulation and manufacture of fill-fished drug products for parenteral applications.

Carbogen Amcis

News

11 August 2016
Dishman Celebrates a Decade of Success Since Acquisition of CARBOGEN AMCIS

2 February 2016
Dishman Netherlands awarded for its Corporate Social Responsibility.

24 September 2015
Dishman has been awarded manufacture of SIRTURO® (bedaquiline) API

9 February 2015
Successful FDA inspection at the Netherlands Dishman site

VIEW NEWS ARCHIVE